Dr. Manish Sagar is an Associate Professor of Medicine at the Boston University School of Medicine. My laboratory is primarily interested in human immunodeficiency virus type 1 (HIV-1) mucosal HIV-1 transmission and antibodies. One of our focus is to understand the biological mechanisms for the selection observed during HIV-1 transmission. Even though chronically infected subjects harbor extensive variants during transmission, only a limited number of viruses are acquired by newly infected partners. Genotypic examination of viruses present in the newly infected subject compared to those circulating in the transmitting partner suggests that the observed genetic bottleneck during transmission is not due to random chance. Laboratory studies explore the hypothesis that during transmission there is selection of specific variants with properties that confer fitness for transmission.
Another focus in the lab is to decipher correlate of immune protection. Even though infants are exposed to infected breast milk, only a small proportion (around 30%) acquire HIV-1 from their infected mother in the absence of antiretroviral protection. We hypothesize that maternally acquired antibodies present in the infant prevent HIV-1 acquisition either through neutralization or antibody dependent cellular cytotoxicity against the variants circulating in the maternal breast milk. Defining the immune correlate of protection will have important implications for HIV-1 vaccine design. Our work focuses on understanding HIV-1 envelope and host antibody evolution and impact on disease pathogenesis.
Dr. Sagar has served on numerous committees including NIH study sections and Doris Duke Charitable Foundation Early Career Development Award Review Committee. He is an active member of the Infectious Diseases Society of America (IDSA).
- Associate Professor, Microbiology, Boston University School of Medicine
- Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Graduate Medical Sciences
- Member, Genome Science Institute, Boston University
- Johns Hopkins University School of Medicine, MD
- Columbia University, BS
- Published on 3/2/2020
Thomas AS, Ghulam-Smith M, Olson A, Coote C, Gonzales O, Sagar M. A new cell line for assessing HIV-1 antibody dependent cellular cytotoxicity against a broad range of variants. J Immunol Methods. 2020 May; 480:112766. PMID: 32135162.
- Published on 1/6/2020
Registre L, Moreau Y, Ataca ST, Pulukuri S, Henrich TJ, Lin N, Sagar M. HIV-1 Coreceptor Usage and Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility. J Virol. 2020 01 06; 94(2). PMID: 31694950.
- Published on 1/7/2019
Pudney J, Wangu Z, Panther L, Fugelso D, Marathe JG, Sagar M, Politch JA, Anderson DJ. Condylomata Acuminata (Anogenital Warts) Contain Accumulations of HIV-1 Target Cells That May Provide Portals for HIV Transmission. J Infect Dis. 2019 01 07; 219(2):275-283. PMID: 30137482.
- Published on 11/1/2018
Olson A, Ragan EJ, Nakiyingi L, Lin N, Jacobson KR, Ellner JJ, Manabe YC, Sagar M. Brief Report: Pulmonary Tuberculosis Is Associated With Persistent Systemic Inflammation and Decreased HIV-1 Reservoir Markers in Coinfected Ugandans. J Acquir Immune Defic Syndr. 2018 11 01; 79(3):407-411. PMID: 30063648.
- Published on 7/9/2018
Pena-Cruz V, Agosto LM, Akiyama H, Olson A, Moreau Y, Larrieux JR, Henderson A, Gummuluru S, Sagar M. HIV-1 replicates and persists in vaginal epithelial dendritic cells. J Clin Invest. 2018 08 01; 128(8):3439-3444. PMID: 29723162.
- Published on 1/1/2018
Thomas AS, Ghulam-Smith M, Sagar M. Neutralization and beyond: Antibodies and HIV-1 acquisition. Curr Top Virol. 2018; 15:73-86. PMID: 31787808.
- Published on 10/24/2017
Ghulam-Smith M, Olson A, White LF, Chasela CS, Ellington SR, Kourtis AP, Jamieson DJ, Tegha G, van der Horst CM, Sagar M. Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity. MBio. 2017 10 24; 8(5). PMID: 29066544.
- Published on 8/4/2016
Gonzalez OA, Sagar M. Antibodies and Acidic Environment Do Not Enhance HIV-1 Transcytosis. J Infect Dis. 2016 Oct 15; 214(8):1221-4. PMID: 27493237.
- Published on 5/5/2016
Lin N, Gonzalez OA, Registre L, Becerril C, Etemad B, Lu H, Wu X, Lockman S, Essex M, Moyo S, Kuritzkes DR, Sagar M. Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants. EBioMedicine. 2016 Jun; 8:237-47. PMID: 27428434.
- Published on 3/12/2015
Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015 Jun 15; 60(12):1842-51. PMID: 25767256.
View 30 more publications: View full profile at BUMC